Diclofenac chemical structure
Find information on thousands of medical conditions and prescription drugs.

Diclofenac

Diclofenac (marketed as Voltaren®, Voltarol®, Diclon® and Cataflam®) is a non-steroidal anti-inflammatory drug (NSAID) taken to reduce inflammation, such as in arthritis or acute injury. It can also be used to reduce menstrual pain. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Voltaren and Voltarol contain the sodium salt of diclofenac. In the United Kingdom Voltarol can be supplied with either the sodium salt or potassium salt, while Cataflam in some other countries is the potassium salt only. Diclofenac is available in stomach acid resistant formulations (25 and 50 mg), fast disintegrating oral formulations (50 mg), slow- and controlled-release forms (75, 100 or 150 mg), suppositories (50 and 100 mg), and injectable forms (50 and 75 mg). Diclofenac is also available over the counter (OTC) in some countries: Voltaren® dolo (12.5 mg diclofenac as potassium salt) in Switzerland and Germany, and preparations with 25 mg diclofenac are OTC in New Zealand. OTC use is approved for minor aches and pains and fever associated with common infections.

Diclofenac is available as a generic drug in a number of formulations.

Mechanism of action

The exact mechanism of action is not entirely known, but it is thought that the primary mechanism responsible for its anti-inflammatory/antipyretic/analgesic action is inhibition of prostaglandin synthesis by inhibition of cyclooxygenase (COX).

Diclofenac, it seems, may also be a unique member of the NSAIDs. There is some evidence that diclofenac inhibits the lipooxygenase pathways, thus reducing formation of the leukotrienes (also pro-inflammatory autacoids). There is also speculation that diclofenac may inhibit phospholipase A2 as part of its mechanism of action. These additional actions may explain the high potency of diclofenac - it is the most potent NSAID on a molar basis.

Inhibition of COX also decreases prostaglandins in the epithelium of the stomach, making it more sensitive to corrosion by gastric acid. This is also the main side effect of diclofenac. Diclofenac has a low to moderate preference to block the COX2-isoenzyme (approximately 10-fold) and is said to have therefore a somewhat lower incidence of gastrointestinal complaints than noted with indomethacin and aspirin.

The action of one single dose is much longer (6 to 8 hours) than the very short half-life of the drug indicates. This could partly be due to a particular high concentration achieved in synovial fluids.

Common uses

Diclofenac is used for musculoskeletal complaints, especially arthritis (rheumatoid arthritis, osteoarthritis, spondylarthritis, ankylosing spondylitis), gout attacks, and pain management in case of kidney stones and gallstones. An additional indication is the treatment of acute migraines. Diclofenac is used commonly to treat mild to moderate post-operative or post-traumatic pain, particular when inflammation is also present, and is effective against menstrual pain.

Read more at Wikipedia.org


[List your site here Free!]


Diclofenac more effective than acetaminophen in osteoarthritis of the knee - Patient Oriented Evidence That Matters: practice recommendations from key
From Journal of Family Practice, 7/1/03 by R. Marc Via

Case JP, Baliumnas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis. A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003; 163:169-178.

* PRACTICE RECOMMENDATIONS

Diclofenac 150 mg/d is more effective in controlling osteoarthritis symptoms than acetaminophen 4 g/d in patients previously requiring an nonsteroidal anti-inflammatory drug (NSAID).

Since acetaminophen is less expensive and better tolerated, it is reasonable to attempt a 2-week trial in all patients prior to initiating treatment with NSAIDs.

* BACKGROUND

A small number of studies have compared the effectiveness of acetaminophen with various NSAIDs, with some studies showing equivalence and others showing acetaminophen coming up short. These studies are the basis on which current clinical guidelines recommend acetaminophen over NSAIDs as initial therapy. This study evaluated the effectiveness of acetaminophen (Tylenol) and diclofenac sodium (Voltaren) compared with placebo in adults with osteoarthritis of the knee.

* POPULATION STUDIED

The 82 patients in this study were men and women aged 40 to 75 years, recruited from a rheumatology clinic, with unilaterally symptomatic osteoarthritis of the knee. Patients had radiographic evidence of osteoarthritis (Kellgren-Lawrence grade [greater than or equal to] 1) and medial compartment involvement.

Clinical criteria for entry were pre-enrollment ambulatory pain assessed by a visual analog score [greater than or equal to] 30 mm on a 100-mm scale; moderate pain, assessed with 5-point Likert scale; or increased pain, evidenced by an increase of [greater or equal to] 10 mm on visual analog scale or [greater then or equal to] 1 on Likert scale when taken off their previous analgesic during the initial 2 weeks of no treatment.

Furthermore, these patients had to be capable of independent ambulation without the use of a cane or walker and were within 1 standard deviation of weight for their height according to an actuarial life insurance table.

* STUDY DESIGN AND VALIDITY

This research was a randomized, double-blind, placebo-controlled study. Initial allocation to treatment groups was concealed. After a 2-week washout period, patients were randomized to receive treatment with diclofenac (75 mg twice daily), acetaminophen (1000 mg 4 times daily), or matching placebo for 12 weeks. Follow-up visits were scheduled at weeks 2 and 12, at which time pain and function were evaluated. Analysis of data was performed on an intention-to-treat basis.

This study was well done; however, some aspects deserve comment. This is a study of the comparative effectiveness of acetaminophen in a group of patients for whom acetaminophen already was shown not to work. All patients were recruited from a rheumatology clinic and had to have increased pain during the 2-week washout period, during which they were not allowed to take any of their previous pain medications.

Most of the patients (71%) were taking an NSAID alone or in combination with acetaminophen before the study started. Because acetaminophen has been advocated as first-line therapy for osteoarthritis for almost 10 years, these patients had very likely tried acetaminophen without success long before the study was started.

Also, there was a marked difference in tolerability between the 2 treatments. Of 82 patients, 21 withdrew prior to week 12. The patients that withdrew from the diclofenac group did so mainly due to adverse effects, whereas those that withdrew from the acetaminophen and placebo groups did so mostly due to ineffectiveness.

* OUTCOMES MEASURED

The primary outcome was efficacy as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 2 and 12 weeks. This instrument assesses pain, stiffness, and function.

* RESULTS

Only patients treated with diclofenac experienced a significant improvement in the primary outcome--the WOMAC--at week 2 (27%; P=.001) and week 12 (25.6%; P=.001) compared with baseline. The individual components (pain, stiffness, and function) of the WOMAC each showed clinical and statistically significant improvement compared with baseline scores at 2 and 12 weeks in the diclofenac-treated group only.

Predictably, when those patients who had previously taken an NSAID were analyzed, there was a significant response in the diclofenac-treated group but not in the acetaminophen or placebo groups. The response from acetaminophen was similar to that seen with placebo and was not significantly different from baseline scores.

R. Marc Via, MD, Department of Family and Community Medicine, Scott & White Memorial Hospital, Texas A & M University System Health Science Center College of Medicine, Temple, Tex. E-mail: mvia@swmail.sw.org.

COPYRIGHT 2003 Dowden Health Media, Inc.
COPYRIGHT 2003 Gale Group

Return to Diclofenac
Home Contact Resources Exchange Links ebay